Recursion achieved a $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells, reaching over $500 million in milestone and upfront payments. The company has approximately $785 million in cash and cash equivalents as of October 9, 2025, with a runway through the end of 2027.

The company delivered a second neuro map to Roche and Genentech, earning a $30 million milestone and surpassing $500 million in upfront and milestone payments. This collaboration aims to accelerate treatments for neurological diseases and gastrointestinal oncology, with potential milestone payments exceeding $10 billion and royalties.

Recursion Pharmaceuticals continues to advance its internal pipeline programs, with REC-617 showing early anti-tumor activity and REC-7735 nominated as a new development candidate. The company is on track for over $100 million in milestone payments by the end of 2026, with multiple neuroscience target validation programs advancing.

Read more at GlobeNewswire: Recursion Reports Third Quarter 2025 Financial Results and